New research has found that breast cancer tumours change their hormonal status throughout the course of disease, whereas the decision about the most effective treatment for the patient is usually only based on one biopsy of the primary tumour.
For some patients, biopsy verifications of any relapse will be very important because it may completely change their clinical management, a Swedish researcher will tell the 2011 European Multidisciplinary Cancer Congress today (Monday 26 September).
Speaking about the study Professor Michael Baumann, ECCO President said:”This finding is of major clinical importance because it shows that many cancer patients who relapse do not receive optimal treatment for their disease. While the price of regular biopsies may seem high for both patients and healthcare systems, in the long run they may avoid inappropriate and costly treatments and, even more importantly, may be the basis for selecting more effective treatments for individual patients.”
Published by OnMedica at: